TRVI
NASDAQ
$16.77
Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $24.90 (+48.48%)
Market Cap
$2.33B
Free Cash Flow Yield
-1.95%
Beta (5Y)
0.65
Price Chart
Valuation
Market Cap$2.33B
P/B14.77
Profitability
EBITDA-$53M
EPS-$0.36
Financial Health
Free Cash Flow Yield-1.95%
Growth & Risk
EPS 5Y CAGR-27.09%
FCF 5Y CAGR+7.30%
Beta (5Y)0.65
Sharpe Ratio1.67